← Eichor
Condition: Premenopausal Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Premenopausal Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
Phase 2 · 1 location(s) · Samsung Medical Center · NCT04819243Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Phase 3 · 1 location(s) · Peking University · NCT02535221Assessment of Brain Cognitive Impairment in Breast Cancer
Phase N/A · 1 location(s) · Tang-Du Hospital · NCT05305092A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Ad
Phase 1 · 15 location(s) · TerSera Therapeutics LLC · NCT07310420Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Phase 2 · 1 location(s) · National Taiwan University Hospital · NCT05720260Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Phase 2 · 15 location(s) · SOLTI Breast Cancer Research Group · NCT05982093PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Phase N/A · 71 location(s) · West German Study Group · NCT05792150Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · 229 location(s) · Novartis Pharmaceuticals · NCT05827081Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients
NA · 1 location(s) · The Netherlands Cancer Institute · NCT06273800Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Develop
Phase 2 · 4 location(s) · National Cancer Institute (NCI) · NCT05941520Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Phase 2 · 11 location(s) · National Cancer Institute (NCI) · NCT06184750A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth
Phase 2 · 78 location(s) · Eli Lilly and Company · NCT07287098The Immune System's Response to Young Women's Breast Cancer
Phase N/A · 5 location(s) · University of Colorado, Denver · NCT01503190PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
Phase N/A · 13 location(s) · International Agency for Research on Cancer · NCT03144648Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Optimize Adjuvant Treatment in Premenopausa
Phase 3 · 49 location(s) · Tokyo Women's Medical University · NCT07671885Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breas
Phase N/A · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT00823654Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT01788839A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovaria
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07159451Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal
Phase 3 · 1249 location(s) · NRG Oncology · NCT05879926Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
Phase 2 · 1 location(s) · National Taiwan University Hospital · NCT06225284OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Phase 4 · 2 location(s) · Gangnam Severance Hospital · NCT05333328Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and E
Phase 2 · 1 location(s) · Yale University · NCT06953882A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05910294Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally A
Phase 2 · 1 location(s) · Mayo Clinic · NCT07460752Insulin Sensitivity After Breast Cancer
NA · 1 location(s) · University of Copenhagen · NCT05010356
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.